Disease activity trajectories from childhood to adulthood in the population-based Nordic juvenile idiopathic arthritis cohort.

Authors:
Rypdal V; Glerup M; Rypdal M; Arnstad E; Aalto K and 8 more

Journal:
RMD Open

Publication Year: 2024

DOI:
10.1136/rmdopen-2023-003759

PMCID:
PMC10928776

PMID:
38458760

Journal Information

Full Title: RMD Open

Abbreviation: RMD Open

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Rheumatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"the unstable results observed when using more than four groups led us to proceed with four groups10 1136/rmdopen-2023-003759 supp3 supplementary data 10 1136/rmdopen-2023-003759 supp1 supplementary data following the approach of shoop-worrall et al we modelled the active joint count using a zero-inflated poisson distribution and phga and paga using normal distributions.; we smoothened the resulting curves using a low-pass filter to obtain better visualisations of the results10 1136/rmdopen-2023-003759 supp2 supplementary data 10 1136/rmdopen-2023-003759 supp4 supplementary data 10 1136/rmdopen-2023-003759 supp5 supplementary data we constructed a heat-map plot by hierarchical clustering to explore factors associated with the paga.; the proportion of active disease according to the acr criteria and a cjadas10>1 was slightly higher when excluding these patients compared with the four groups when all the patients were included ( table 3 ) 10 1136/rmdopen-2023-003759 supp6 supplementary data 10 1136/rmdopen-2023-003759 supp7 supplementary data table 4 cjadas10 and components at the three major visits for each trajectory group in the nordic juvenile idiopathic arthritis cohort n baseline n 8-year follow-up n 18-year follow-up p value* group 1 (mida-id) cjadas10 70 1 7 (0-3 9) 101 0 (0-0 1) 147 0 (0-0 5) <0 0001 0 40 active joint count 168 0 (0-1 0) 168 0 (0-0) 167 0 (0-0) <0 0001 0 03 paga 84 0 5 (0-1 5) 123 0 (0-0) 151 0 (0-0 5) <0 0001 0 01 phga 73 0 5 (0-1 0) 103 0 (0-0) 163 0 (0-0) <0 0001 0 45 group 2 (mida-mda) cjadas10 55 2 2 (1 5-4 5) 78 1 5 (0-3 7) 94 4 0 (1 5-8 5) 0 20 0 008 active joint count 104 0 (0-1 0) 101 0 (0-1 0) 104 0 (0-1 0) 0 36 0 50 paga 65 0 5 (0-1 5) 83 0 2 (0-1 2) 95 2 0 (0 5-4 5) 0 28 <0 0001 phga 57 0 9 (0 3-1 2) 81 0 5 (0-1 5) 101 1 0 (0-2 0) 0 29 <0 0001 group 3 (hda-mida) cjadas10 71 8 4 (5 0-12 7) 85 1 5 (0 2-4 0) 113 1 0 (0-3 0) <0 0001 0 33 active joint count 119 3 0 (2 0-5 0) 115 0 (0-1) 119 0 (0-0) <0 0001 0 0004 paga 76 2 2 (1 0-4 3) 89 0 4 (0-1 9) 115 0 5 (0-2 0) <0 0001 <0 0001 phga 72 2 4 (1 0-4 2) 86 0 3 (0-1 3) 116 0 (0-0 5) <0 0001 0 58 group 4 (hda-hda) cjadas10 26 13 8 (6 6-19 0) 27 7 8 (2 6-15 5) 35 10 0 (6 5-14 0) 0 08 0 46 active joint count 36 4 0 (2 5-10 0) 36 2 5 (0-6 0) 36 2 0 (0-3 5) 0 01 0 38 paga 26 2 8 (1 0-6 2) 28 1 9 (0 5-5 1) 35 4 0 (2 0-7 5) 0 99 <0 0001 phga 27 4 4 (2 0-5 1) 29 2 3 (0 8-5 0) 36 3 0 (1 0-4 5) 0 39 <0 0001 disease activity trajectory groups from baseline to 18-year follow-up."

Code Sharing
Evidence found in paper:

"Competing interests: None declared."

Evidence found in paper:

"Funding: The work was supported by postdoctoral grants from the Helse Nord Research Program."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025